Straits Times Index
3,265.95 +1.42 (+0.04%) S&P 500
5,211.42 +23.75 (+0.46%) Dow
39,380.65 +324.26 (+0.83%) Nasdaq
16,343.59 +40.84 (+0.25%) Bitcoin USD
62,335.88 +108.16 (+0.17%) CMC Crypto 200
1,340.79 +40.69 (+3.13%)
Nexalin Technology, Inc. (NXL)
| Previous close | 1.2100 |
| Open | 1.2400 |
| Bid | 1.1700 x 100 |
| Ask | 1.2000 x 100 |
| Day's range | 1.1400 - 1.2400 |
| 52-week range | 0.2530 - 3.4000 |
| Volume | |
| Avg. volume | 848,380 |
| Market cap | 8.812M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireJoin Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
HOUSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on May 23, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. A l
- GlobeNewswire
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on April 23, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2). Mark White, CEO of Nexalin, stated, “We remain committed to our mission of revolutionizing the treatment of mental health and neurological condi
- GlobeNewswire
Nexalin Technology CEO Provides Letter to Shareholders
Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic modelHOUSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided the following letter to shareholders from the Company’s CEO, Mark White, including updates regarding the growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as, prog
